City Ventures Expands Access to Homeownership with Limited Selection of Affordable Homes at Pinnacle in Milpitas
'We're incredibly proud to partner with the City of Milpitas to bring more choices and possibilities for first-time buyers who are looking to put down roots,' said Natasha Zabaneh, President of City Ventures.
Share
'We're incredibly proud to partner with the City of Milpitas to bring more choices and possibilities for first-time buyers who are looking to put down roots,' said Natasha Zabaneh, President of City Ventures. 'This opportunity is a reflection of our commitment to create strong, inclusive communities––not just in Milpitas, but throughout California.'
The BMR program at Pinnacle features its popular Plan One and Plan Two designs, both offering brand-new, all-electric construction, owned solar panels, Nest thermostats, Ring doorbells, keyless entry, energy-efficient appliances. Inviting kitchens feature soft-close drawers and doors, quartz or granite countertops, designer fixtures, and efficient, induction cooktops, while outdoor decks offer beautiful spaces for entertaining and relaxing. Plan One––priced at $707,000 with a monthly HOA fee of $219––offers approximately 1,064 square feet of thoughtfully planned living space, with two bedrooms and two baths. Plan Two BMR homes are sold out.
The housing market in popular Milpitas remains extremely competitive. According to Redfin, during June the median sales price for a home in the city was just over $1.6 million, with just 1.1 months of inventory available for potential home buyers. In addition, given that nearly 60% of listings sold over list price with a median time on market of just 18 days, these BMR plans at Pinnacle provide a unique opportunity for eligible households to grab their rung on the homebuying ladder in the 'Crossroads of Silicon Valley.' To date, Pinnacle's success has been notable––more than 70% of homes are sold before model homes have had a chance to open.
'Buyers love Pinnacle's highly desirable location, right in the center of everything that matters,' said Zabaneh. 'Enjoy endless attractions at your doorstep, top-rated neighborhood schools, and convenient access to world-renowned employers throughout the Silicon Valley.' With its central Milpitas location, Pinnacle is just minutes away from multiple shopping, restaurant and recreation opportunities including Northern California's largest indoor outlet mall, the 1,558-acre Ed R. Levin County Park, the Milpitas Sports Center, 30 local parks and two public golf courses.
Interested buyers are strongly encouraged to act quickly on this unique opportunity. To begin the application process, send an email to Pinnacle@CityVentures.com. Income limits and other restrictions apply. Pinnacle is located at 1756 Houret Court in Milpitas. Additional information about Pinnacle, including floorplans and community details, are available online at www.CityVentures.com/Pinnacle_BMR.
City Ventures, California's leading homebuilder, focuses on 'Building It Forward' by repositioning underutilized real estate into residential housing in supply-constrained coastal urban infill areas and high-demand suburban locations. To date, the builder has constructed 4,900 townhomes, condominiums, lofts, mixed-use, live-work, and single-family detached homes throughout Southern and Northern California. City Ventures was named 2023 Builder of the Year by the national magazine Builder & Developer and is celebrating 15 years of homebuilding this year. Based in San Francisco and Irvine, City Ventures currently owns and controls over 8,000 lots in California. For more information, please visit www.cityventures.com. You can also follow City Ventures on social media on Facebook (@cityventures), Instagram (@city_ventures) and YouTube (@cityventures).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Berkshire Stock Sees Weird Trading. The A Shares Pop While B Shares Dip.
It is unclear what caused the late-day buying in the A shares, but it looks like it will reverse Friday.
Yahoo
5 hours ago
- Yahoo
VeriSign (VRSN) Announced Increased Earnings
In July 2025, VeriSign expanded its buyback authorization and announced increased earnings, alongside a declared cash dividend. Despite these positive developments, the company's share price declined by 5.90% over the past month. This decline coincided with a broader market downturn, driven by global tariff uncertainties and disappointing job data. While VeriSign's solid financial results might have typically buoyed investor confidence, the market context placed downward pressure on its stock. The company's follow-on equity offering also added complexity to its share dynamics over this period, contributing to a challenging market performance. Every company has risks, and we've spotted 3 warning signs for VeriSign (of which 1 shouldn't be ignored!) you should know about. Rare earth metals are the new gold rush. Find out which 25 stocks are leading the charge. VeriSign's recent expansion of its buyback authorization and earnings increase, juxtaposed with a share price decline of 5.90% during July, showcases the complexity of market dynamics. This decline coincided with external market pressures like global tariff uncertainties and disappointing job data. Despite these pressures, VeriSign's solid financial results and strategic initiatives may support long-term growth. Notably, in the last year, VeriSign's total return, including dividends, was 41.76%, highlighting its strong performance over a broader timeline despite recent challenges. Comparatively, over the past year, VeriSign outperformed the US market, which returned 16.8%, and also exceeded the US IT industry with its 24.5% return. The company's ongoing initiatives, such as improving domain registration trends and marketing strategies, could positively impact revenue growth, while the introduction of dividends reflects financial stability that could enhance earnings forecasts. VeriSign's current share price of US$265.37 is below the analyst consensus price target of US$309.0, indicating a 16.44% discount, which resonates with the potential for value growth should the company's revenue and earnings forecasts materialize as expected. In light of our recent valuation report, it seems possible that VeriSign is trading beyond its estimated value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include VRSN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 hours ago
- Yahoo
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
CRISPR Therapeutics recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements. We've spotted 1 risk for CRISPR Therapeutics you should be aware of. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices. The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges. The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
